Donate

Patient Webinar: What’s New in Hodgkin Lymphoma

Lymphoma Australia invites you to our next free educational webinar for patients and carers with renowned expert Associate Professor Nicole Wong Doo, Haematologist at Concord Repatriation General Hospital, Sydney.

In this webinar, Dr Wong Doo will provide valuable insights into Hodgkin Lymphoma, including current management strategies, recent treatment developments, and what the future of care may look like.

Event Details

Date: Wednesday 12th August 2026
Time: 4:00pm to 5:00pm (NSW/VIC/QLD/ACT/TAS)
3:30pm to 4:30pm (SA/NT)
1:00pm to 2:00pm (WA)
Location: Online via Zoom – Link sent on registration
Cost: Free – Registration Required

Guest Presenter

Associate Professor Nicole Wong Doo is a Haematologist at Concord Repatriation General Hospital, senior lecturer at the University of Sydney and NSW Councillor for the Haematology Society of Australia and New Zealand.

As Director of the Haematology Clinical Research Unit at Concord Hospital since 2022, she leads a team of 20 in the delivery of clinical trials embedded within clinical practice and clinical-translational research. She is a principal investigator of a number of lymphoma and myeloma clinical trials.

With a growing profile in research focused on listening to patients’ voice through patient-reported outcomes (PRO) research, she leads a PRO study investigating patients’ unmet needs during therapy for blood diseases and is co-PI of MyHodgkin MyHealth, a mobile App for patient-entered health outcomes in Hodgkin lymphoma.

My Hodgkin, My Health (MHMH) App

In a new era of Hodgkin lymphoma (HL) treatment, understanding long-term health outcomes is more important than ever. My Hodgkin, My Health (MHMH) is the first app designed specifically to help HL patients document their health journey, connect with personalised follow-up, and contribute valuable data to HL research.



More Information on MHMH

There is limited availability for this event, so secure your spot quickly.
This event has already taken place.
Details
Date: Wednesday 12th of August 2026
Time: 4:00pm AEST - 5:00pm AEST

For more info email: nurse@lymphoma.org.au or phone 1800 953 081.
Watch recording
Download Flyer

Support and information

Support Groups & Social Media

Find Out More

Factsheets & Booklets

Find Out More

Fundraise for us

Get started

Cart
Checkout - $0.00
  • 0
  • 1

Contact Lymphoma Australia Today!

Patient Support Hotline

General Enquiries

Please note:
Lymphoma Australia staff are only able to reply to emails sent in English language.

Useful Definitions

  • Refractory: This means the lymphoma does not get better with treatment. The treatment didn’t work as hoped.
  • Relapsed: This means the lymphoma came back after being gone for a while after treatment.
  • 2nd line treatment: This is the second treatment you get if the first one didn’t work (refractory) or if the lymphoma comes back (relapse).
  • 3rd line treatment: This is the third treatment you get if the second one didn’t work or the lymphoma comes back again.
  • Approved: Available in Australia and listed by the Therapeutics Goods Administration (TGA).
  • Funded: Costs are covered for Australian citizens. This means if you have a Medicare card, you shouldn’t have to pay for the treatment.[WO7]

You need healthy T-cells to make CAR T-cells. For this reason, CAR T-cell therapy cannot be used if you have a T-cell lymphoma – yet.

For more information on CAR T-cells and T-cell lymphoma click here. 

Special Note: Although your T-cells are removed from your blood for CAR T-cell therapy, most of our T-cells live outside of our blood – in our lymph nodes, thymus, spleen and other organs.